Go Pro
→ ALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I. (From Brownstone Research) (Ad)tc pixel Free HEMO Stock Alerts

Hemogenyx Pharmaceuticals (HEMO) Competitors

Hemogenyx Pharmaceuticals logo
GBX 620 -20.00 (-3.13%)
As of 12:28 PM Eastern
Compare

HEMO vs. ARIX, BTG, CIR, TILS, and VSN

Should you buy Hemogenyx Pharmaceuticals stock or one of its competitors? MarketBeat compares Hemogenyx Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hemogenyx Pharmaceuticals include Arix Bioscience (ARIX), BTG (BTG), Circassia Group (CIR), Tiziana Life Sciences (TILS), and Verseon (VSN). These companies are all part of the "biotechnology" industry.

How does Hemogenyx Pharmaceuticals compare to Arix Bioscience?

Hemogenyx Pharmaceuticals (LON:HEMO) and Arix Bioscience (LON:ARIX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

Arix Bioscience has higher revenue and earnings than Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A
Arix Bioscience£14.16M0.00£14.96M£0.11N/A

Hemogenyx Pharmaceuticals has a beta of 1.53, indicating that its share price is 53% more volatile than the broader market. Comparatively, Arix Bioscience has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market.

0.1% of Hemogenyx Pharmaceuticals shares are held by institutional investors. Comparatively, 41.3% of Arix Bioscience shares are held by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are held by company insiders. Comparatively, 20.7% of Arix Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Arix Bioscience has a net margin of 105.64% compared to Hemogenyx Pharmaceuticals' net margin of 0.00%. Arix Bioscience's return on equity of 6.41% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hemogenyx PharmaceuticalsN/A -2,807.75% -37.79%
Arix Bioscience 105.64%6.41%2.18%

In the previous week, Hemogenyx Pharmaceuticals' average media sentiment score of 0.00 equaled Arix Bioscience'saverage media sentiment score.

Company Overall Sentiment
Hemogenyx Pharmaceuticals Neutral
Arix Bioscience Neutral

Summary

Arix Bioscience beats Hemogenyx Pharmaceuticals on 9 of the 10 factors compared between the two stocks.

How does Hemogenyx Pharmaceuticals compare to BTG?

Hemogenyx Pharmaceuticals (LON:HEMO) and BTG (LON:BTG) are related small-cap companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

In the previous week, BTG had 3 more articles in the media than Hemogenyx Pharmaceuticals. MarketBeat recorded 3 mentions for BTG and 0 mentions for Hemogenyx Pharmaceuticals. BTG's average media sentiment score of 0.17 beat Hemogenyx Pharmaceuticals' score of 0.00 indicating that BTG is being referred to more favorably in the news media.

Company Overall Sentiment
Hemogenyx Pharmaceuticals Neutral
BTG Neutral

0.1% of Hemogenyx Pharmaceuticals shares are held by institutional investors. Comparatively, 20.3% of BTG shares are held by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are held by insiders. Comparatively, 19.7% of BTG shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

BTG has a consensus price target of GBX 160, indicating a potential upside of 50.94%. Given BTG's stronger consensus rating and higher probable upside, analysts plainly believe BTG is more favorable than Hemogenyx Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hemogenyx Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
BTG
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

BTG's return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hemogenyx PharmaceuticalsN/A -2,807.75% -37.79%
BTG N/A N/A N/A

BTG has higher revenue and earnings than Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A
BTG£168.50M1.01N/A£5.1020.78

Summary

BTG beats Hemogenyx Pharmaceuticals on 12 of the 12 factors compared between the two stocks.

How does Hemogenyx Pharmaceuticals compare to Circassia Group?

Circassia Group (LON:CIR) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

Circassia Group's return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Circassia GroupN/A N/A N/A
Hemogenyx Pharmaceuticals N/A -2,807.75%-37.79%

0.1% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Circassia Group has higher revenue and earnings than Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Circassia Group£27.90M0.00N/A£0.01N/A
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A

In the previous week, Circassia Group's average media sentiment score of 0.00 equaled Hemogenyx Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Circassia Group Neutral
Hemogenyx Pharmaceuticals Neutral

Summary

Circassia Group beats Hemogenyx Pharmaceuticals on 5 of the 7 factors compared between the two stocks.

How does Hemogenyx Pharmaceuticals compare to Tiziana Life Sciences?

Hemogenyx Pharmaceuticals (LON:HEMO) and Tiziana Life Sciences (LON:TILS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

In the previous week, Tiziana Life Sciences had 7 more articles in the media than Hemogenyx Pharmaceuticals. MarketBeat recorded 7 mentions for Tiziana Life Sciences and 0 mentions for Hemogenyx Pharmaceuticals. Tiziana Life Sciences' average media sentiment score of 0.82 beat Hemogenyx Pharmaceuticals' score of 0.00 indicating that Tiziana Life Sciences is being referred to more favorably in the news media.

Company Overall Sentiment
Hemogenyx Pharmaceuticals Neutral
Tiziana Life Sciences Positive

Tiziana Life Sciences has lower revenue, but higher earnings than Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A
Tiziana Life Sciences-£3.60M0.00N/A-£16.30N/A

0.1% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Tiziana Life Sciences' return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hemogenyx PharmaceuticalsN/A -2,807.75% -37.79%
Tiziana Life Sciences N/A N/A N/A

Summary

Tiziana Life Sciences beats Hemogenyx Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

How does Hemogenyx Pharmaceuticals compare to Verseon?

Hemogenyx Pharmaceuticals (LON:HEMO) and Verseon (LON:VSN) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Verseon's return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hemogenyx PharmaceuticalsN/A -2,807.75% -37.79%
Verseon N/A N/A N/A

Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A
VerseonN/AN/AN/A-£14.30N/A

In the previous week, Hemogenyx Pharmaceuticals' average media sentiment score of 0.00 equaled Verseon'saverage media sentiment score.

Company Overall Sentiment
Hemogenyx Pharmaceuticals Neutral
Verseon Neutral

0.1% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Hemogenyx Pharmaceuticals and Verseon tied by winning 3 of the 6 factors compared between the two stocks.

Get Hemogenyx Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for HEMO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HEMO vs. The Competition

Export
MetricHemogenyx PharmaceuticalsBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£42.16M£3.60B£6.92B£2.87B
Dividend YieldN/A3.77%2.60%6.13%
P/E Ratio-3.637.67281.14369.49
Price / SalesN/A1,219.22575.4083,955.53
Price / Cash2.05103.0171.7927.89
Price / Book2,516.6617.0312.867.07
Net Income-£6.89K-£12.50M£3.49B£5.89B
7 Day Performance0.81%2.90%2.60%1.18%
1 Month Performance-22.21%-4.47%-2.67%0.90%
1 Year Performance311.96%54.18%75.98%75.31%

Hemogenyx Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HEMO
Hemogenyx Pharmaceuticals
N/AGBX 620
-3.1%		N/A+345.8%£42.16MN/AN/A14
ARIX
Arix Bioscience
N/AN/AN/AN/A£183.73M£14.16M1,290.919
BTG
BTG
4.021 of 5 stars		GBX 105.77
-0.2%		GBX 160
+51.3%		N/A£170.45M£159.40M17.634,690
CIR
Circassia Group
N/AN/AN/AN/A£142.66M£27.90M3,400.00111
TILS
Tiziana Life Sciences
N/AN/AN/AN/A£113.85M-£3.60MN/A11

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:HEMO) was last updated on 8/6/2026 by MarketBeat.com Staff.
From Our Partners
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
This AI fund sends investors payouts every Thursday
CrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...
Investors Alley | Sponsoredtc pixel
A Wall Street Veteran's Weekly Trade for Any Market Condition
Dave Aquino spent 25 years at Merrill Lynch and Vanguard studying one weekly options play that worked in bull,...
Base Camp Trading | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
This under $7 stock could be.
Just one mile from SpaceX's launchpad sits a small company doing something SpaceX can't - and it still trades ...
Freedom Financial | Sponsoredtc pixel
The dollar reset no one told you about
Porter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...
Porter & Company | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel